PT  - JOURNAL ARTICLE
AU  - Knight, Stephen R
AU  - Ho, Antonia
AU  - Pius, Riinu
AU  - Buchan, Iain
AU  - Carson, Gail
AU  - Drake, Thomas M
AU  - Dunning, Jake
AU  - Fairfield, Cameron J
AU  - Gamble, Carrol
AU  - Green, Christopher A
AU  - Gupta, Rishi
AU  - Halpin, Sophie
AU  - Hardwick, Hayley E
AU  - Holden, Karl A
AU  - Horby, Peter W
AU  - Jackson, Clare
AU  - Mclean, Kenneth A
AU  - Merson, Laura
AU  - Nguyen-Van-Tam, Jonathan S
AU  - Norman, Lisa
AU  - Noursadeghi, Mahdad
AU  - Olliaro, Piero L
AU  - Pritchard, Mark G
AU  - Russell, Clark D
AU  - Shaw, Catherine A
AU  - Sheikh, Aziz
AU  - Solomon, Tom
AU  - Sudlow, Cathie
AU  - Swann, Olivia V
AU  - Turtle, Lance CW
AU  - Openshaw, Peter JM
AU  - Baillie, J Kenneth
AU  - Semple, Malcolm G
AU  - Docherty, Annemarie B
AU  - Harrison, Ewen M
AU  - ,
TI  - Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score
AID  - 10.1101/2020.07.30.20165464
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.30.20165464
4099  - http://medrxiv.org/content/early/2020/08/02/2020.07.30.20165464.short
4100  - http://medrxiv.org/content/early/2020/08/02/2020.07.30.20165464.full
AB  - Objectives To develop and validate a pragmatic risk score to predict mortality for patients admitted to hospital with covid-19.Design Prospective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical Characterisation Consortium [4C]). Model training was performed on a cohort of patients recruited between 6 February and 20 May 2020, with validation conducted on a second cohort of patients recruited between 21 May and 29 June 2020.Setting 260 hospitals across England, Scotland, and Wales.Participants Adult patients (≥18 years) admitted to hospital with covid-19 admitted at least four weeks before final data extraction.Main outcome measures In-hospital mortality.Results There were 34 692 patients included in the derivation dataset (mortality rate 31.7%) and 22 454 in the validation dataset (mortality 31.5%). The final 4C Mortality Score included eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea, and C-reactive protein (score range 0-21 points). The 4C risk stratification score demonstrated high discrimination for mortality (derivation cohort: AUROC 0.79; 95% CI 0.78 − 0.79; validation cohort 0.78, 0.77-0.79) with excellent calibration (slope = 1.0). Patients with a score ≥15 (n = 2310, 17.4%) had a 67% mortality (i.e., positive predictive value 67%) compared with 1.0% mortality for those with a score ≤3 (n = 918, 7%; negative predictive value 99%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (AUROC range 0.60-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73).Conclusions We have developed and validated an easy-to-use risk stratification score based on commonly available parameters at hospital presentation. This outperformed existing scores, demonstrated utility to directly inform clinical decision making, and can be used to stratify inpatients with covid-19 into different management groups. The 4C Mortality Score may help clinicians identify patients with covid-19 at high risk of dying during current and subsequent waves of the pandemic.Study registration ISRCTN66726260Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org and declare: AB Docherty reports grants from Department of Health and Social Care, during the conduct of the study; grants from Wellcome Trust, outside the submitted work; CA Green reports grants from DHSC National Institute of Health Research UK, during the conduct of the study; PW Horby reports grants from Wellcome Trust / Department for International Development / Bill and Melinda Gates Foundation, grants from NIHR, during the conduct of the study; JS Nguyen-Van-Tam reports grants from Department of Health and Social Care, England, during the conduct of the study; and is seconded to the Department of Health and Social Care, England (DHSC); MN is supported by a Wellcome Trust investigator award and the NIHR University College London Hospitals Biomedical Research Centre (BRC). PJM Openshaw reports personal fees from consultancies and from European Respiratory Society; grants from MRC, MRC Global Challenge Research Fund, EU, NIHR BRC, MRC/GSK, Wellcome Trust, NIHR (HPRU in Respiratory Infection), and NIHR Senior Investigator outside the submitted work. His role as President of the British Society for Immunology was unpaid but travel and accommodation at some meetings was provided by the Society. JK Baillie reports grants from Medical Research Council UK; MG Semple reports grants from DHSC National Institute of Health Research UK, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, during the conduct of the study; other from Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. L Turtle reports grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, during the conduct of the study and grants from the Wellcome Trust outside the submitted work. EM Harrison, H Ardwick, J Dunning, R Gupta, R Pius, L Norman, KA Holden, JM Read, G Carson, L Merson, J Lee, D Plotkin, L Sigfrid, S Halpin, C Jackson, and C Gamble, all declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialISRCTN66726260Clinical Protocols https://isaric4c.net/protocols/ Funding StatementThis work is supported by grants from: the National Institute for Health Research (NIHR) [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059] and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [award 200907], NIHR HPRU in Respiratory Infections at Imperial College London with PHE [award 200927], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], and Liverpool Experimental Cancer Medicine Centre (Grant Reference: C18616/A25153), NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013], EU Platform foR European Preparedness Against (Re-) emerging Epidemics (PREPARE) [FP7 project 602525] and NIHR Clinical Research Network for providing infrastructure support for this research. PJMO is supported by a NIHR Senior Investigator Award [award 201385]. LT is supported by the Wellcome Trust [award 205228/Z/16/Z]. MN is funded by a WT investigator award (207511/Z/17/Z) and the NIHR University College London Hospitals Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust or PHE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the South Central Oxford C Research Ethics Committee in England (Ref: 13/SC/0149), and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028). The study was registered at https://www.isrctn.com/ISRCTN66726260.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe welcome applications for data and material access via our Independent Data And Material Access Committee (https://isaric4c.net). https://isaric4c.net/sample_access